Trump announces deal to lower weight loss drug prices in some cases
President Trump made a groundbreaking announcement on Thursday regarding a deal that would significantly reduce the cost of weight loss drugs for certain Americans. The deal involves the two largest pharmaceutical companies, Eli Lilly and Novo Nordisk, offering their popular GLP-1 weight loss drugs at discounted prices.
During a press conference in the Oval Office, President Trump revealed that under this agreement, Eli Lilly’s Zepbound and Novo Nordisk’s Ozempic and Wegovy will be available at a reduced cost for eligible patients on Medicare, Medicaid, and users of the upcoming “TrumpRx” pharmaceutical website. The average monthly price for most eligible individuals will range from $245 to $350, a substantial decrease from the current price of up to $1,350 per month.
The negotiations for this deal were described as challenging by President Trump, with Health and Human Services Secretary Robert F. Kennedy Jr. noting that it took months to reach an agreement with the pharmaceutical companies. In addition to lowering the prices of weight loss drugs, Eli Lilly and Novo Nordisk have also agreed to offer all their other medications at competitive rates, aligning with most-favored-nation pricing.
The implementation of TrumpRx, expected to launch by the end of the year, will allow customers to purchase prescription drugs directly from pharmaceutical companies without insurance involvement. The cost for injections of Ozempic and Wegovy through TrumpRx is estimated to be around $350 per month, with potential oral GLP-1 drugs priced at $149 per month if approved by the FDA.
Eligible patients on Medicare and Medicaid will benefit from the reduced prices, with costs ranging from $245 to $350 per month for various medications. The criteria for eligibility include specific health conditions and body mass index levels, targeting individuals who stand to benefit the most from weight loss drugs.
The administration aims to promote overall health and well-being through these initiatives, emphasizing the importance of preventing chronic diseases associated with obesity. While the announcement has been met with enthusiasm, some analysts question the impact of most-favored-nation pricing on Medicaid users, citing existing protections in place for the program.
President Trump’s commitment to lowering drug prices and promoting healthier lifestyles is evident in these efforts, which also include plans to improve nutrition in schools and increase physical activity. The administration’s focus on addressing the obesity epidemic aligns with the goal of enhancing public health and reducing healthcare costs in the long run.
Contributed by Aaron Navarro to this report, the announcement of this deal marks a significant step towards making weight loss drugs more accessible and affordable for Americans in need.
